Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

Mol Cancer. 2021 Nov 29;20(1):151. doi: 10.1186/s12943-021-01438-z.

¹ Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy.
² Medical Oncology 1, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
³ Present Address: Precision Medicine Breast Cancer Unit, Scientific Directorate, Health of Woman and Child Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
⁴ Pathology, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
⁵ Specialization School in Oncology, Sapienza University of Rome, Rome, Italy.
⁶ Radiology and Diagnostic Imaging, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
⁷ Biostatistical Unit, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
⁸ Scientific Direction, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
⁹ Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
¹⁰ Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. patrizio.giacomini@ifo.gov.it.

^# Contributed equally.

No abstract available

Keywords: Circulating tumor DNA; HER2+ breast cancer; Liquid biopsy; Pharmacological resistance; T-DM1.

Publication types